<DOC>
	<DOC>NCT01338818</DOC>
	<brief_summary>This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder</brief_summary>
	<brief_title>Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1. Completion of the 40week core study CRIT124D2302 and Week 40 (End of Study) assessments or Patients who meet predefined criteria for treatment failure, were withdrawn from the core study, and have completed corestudy week 40 assessments (Premature Discontinuation Visit) 1. Patients who, during the core study, developed any psychiatric condition that requires treatment with medication or that may interfere with study participation and /or study assessments. 2. Patients who during the core study developed cardiovascular disorders. 3. Pregnant women. 4. Patients who developed seizures during the core study. 5. Diagnosis of glaucoma, hyperthyroidism, pheochromocytoma. 6. Diagnosis or family history of Tourette's syndrome. 7. Patients who during the core study developed cerebrovascular disorders such as cerebral aneurysm, vascular abnormalities including vasculitis and stroke Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Attention Deficit /Hyperactivity Disorder,</keyword>
	<keyword>hyperactivity</keyword>
</DOC>